ProMIS Neurosciences Inc reports results for the quarter ended March 31 - Earnings Summary
13/05/2025 07:16
ProMIS Neurosciences Inc PMN.OQ reported a quarterly adjusted loss of 21 cents per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -19 cents. The lone analyst forecast for the quarter was for a loss of 12 cents per share. Reported revenue was zero; analysts expected zero. ProMIS Neurosciences Inc's reported EPS for the quarter was a loss of 21 cents. The company reported a quarterly loss of $7.35 million. ProMIS Neurosciences Inc shares had fallen by 28.0% this quarter and lost 47.1% so far this year. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy." Wall Street's median 12-month price target for ProMIS Neurosciences Inc is $6.00 This summary was machine generated from LSEG data May 13 at 06:16 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.12 | -0.21 | Missed |
| Dec. 31 2024 | -0.14 | -0.01 | Beat |
| Sep. 30 2024 | -0.07 | 0.42 | Beat |
| Jun. 30 2024 | -0.14 | -0.13 | Beat |